Bahrain to buy one million Valneva COVID-19 vaccine doses

TDT | Manama

The Daily Tribune – www.newsofbahrain.com

Bahrain has signed an agreement with French-based company Valneva SE to supply one million doses of its coronavirus (COVID-19) vaccine known as VLA2001. The announcement of the advance purchase agreement was made yesterday, said a company statement.

This is the second purchase agreement Valneva has secured for VLA2001 since reporting positive data for its Phase 3 clinical trial Cov-Compare. Valneva has initiated a rolling submission process with the Bahraini National Health Regulatory Authority (NHRA).

Franck Grimaud, Chief Business Officer of Valneva, said: “We are grateful to the Bahraini government for their trust and confidence in our vaccine and are eager to work with them to start helping to address the pandemic evolution in the Middle East.

Subject to regulatory review and approval, we plan to start deliveries in the first quarter of 2022.” Last month, Valneva announced that the European Commission signed an advanced purchase agreement for up to 60 million doses of VLA20011.

In October, Valneva reported positive results from the Phase 3 trial Cov-Compare of its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001. The trial recruited a total of 4,012 participants 18 and older across 26 trial sites in the UK.